

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

Supplemental References:

- 1 Goto Y, Sekine I, Tanioka M, et al. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. *Investigational new drugs* 2012;30:1548-1556.
- 2 Vonderheide RH, Burg JM, Mick R, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. *Oncoimmunology* 2013;2:e23033.
- 3 Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors. *Journal of Clinical Oncology* : official journal of the American Society of Clinical Oncology 2010;28:154-159.
- 4 Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. *The Lancet Oncology* 2010;11:38-47.
- 5 Boccia RV, Cosgriff TM, Headley DL, et al. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. *Clinical Colorectal Cancer* 2010;9:102-107.
- 6 Ocvirk J, Brodowicz T, Wrba F, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: Cecoc trial. *World Journal of Gastroenterology* 2010;16:3133-3143.
- 7 Clement-Duchene C, Krupitskaya Y, Ganjoo K, et al. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. *Journal of Thoracic Oncology* : official publication of the International Association for the Study of Lung Cancer 2010;5:1821-1825.
- 8 Casey EM, Harb W, Bradford D, et al. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzalutamide or placebo in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. *Journal of Thoracic Oncology* : official publication of the International Association for the Study of Lung Cancer 2010;5:1815-1820.
- 9 Herbst RS, Kelly K, Chansky K, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. *Journal of Clinical Oncology* : official journal of the American Society of Clinical Oncology 2010;28:4747-4754.
- 10 Colucci G, Giuliani F, Garufi C, et al. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A Gruppo Oncologico dell'Italia Meridionale multicenter phase II study. *Oncology* 2010;79:415-422.
- 11 Brufsky A, Hoelzer K, Beck T, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. *Clinical Breast Cancer* 2011;11:211-220.
- 12 Fischer JR, Griesinger F, Fink T, et al. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)—results of the nonrandomised phase II study TAXERB. *Lung Cancer* 2012;75:348-352.
- 13 Kohne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. *Journal of Cancer Research and Clinical Oncology* 2012;138:65-72.
- 14 Cohen EE, Subramanian J, Gao F, et al. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): Erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. *Clinical Lung Cancer* 2012;13:123-128.
- 15 Niho S, Kunitoh H, Nokihara H, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. *Lung Cancer* 2012;76:362-367.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 16 Stevenson JP, Langer CJ, Somer RA, et al. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous non-small cell lung cancer. *Cancer* 2012;118:5580-5587.
- 17 Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase ii trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:2509-2515.
- 18 Kentepozidis N, Kotsakis A, Soutati A, et al. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: A multicenter phase ii study of the hellenic oncology research group. *Cancer chemotherapy and pharmacology* 2013;71:605-612.
- 19 Balar AV, Apolo AB, Ostrovnya I, et al. Phase ii study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:724-730.
- 20 Kim HR, Jung KH, Im SA, et al. Multicentre phase ii trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (kcsq br-0905). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1485-1490.
- 21 Yoshino T, Hasegawa Y, Takahashi S, et al. Platinum-based chemotherapy plus cetuximab for the first-line treatment of japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of a phase ii trial. *Japanese journal of clinical oncology* 2013;43:524-531.
- 22 Sohal DP, Metz JM, Sun W, et al. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. *Cancer chemotherapy and pharmacology* 2013;71:1485-1491.
- 23 Urata Y, Okamoto I, Takeda M, et al. Phase 2 study of s-1 and carboplatin plus bevacizumab followed by maintenance s-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer. *Cancer* 2013;119:2275-2281.
- 24 Brodowicz T, Ciuleanu TE, Radosavljevic D, et al. Folfox4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with kras wild-type metastatic colorectal cancer: A randomized phase ii cecog study. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1769-1777.
- 25 Yu KD, Liu GY, Chen CM, et al. Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive her2-positive breast cancers, especially in luminal-b subtype, compared with a once-every-3-weeks schedule. *The oncologist* 2013;18:511-517.
- 26 Ji JH, Park SH, Lee J, et al. Prospective phase ii study of neoadjuvant folfox6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. *Cancer chemotherapy and pharmacology* 2013;72:223-230.
- 27 Richards D, Kocs DM, Spira AI, et al. Results of docetaxel plus oxaliplatin (docox) +/- cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised phase 2 study. *European journal of cancer* 2013;49:2823-2831.
- 28 Schmid-Bindert G, Gebbia V, Mayer F, et al. Phase ii study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. *Lung cancer* 2013;81:428-434.
- 29 Chaft JE, Rusch V, Ginsberg MS, et al. Phase ii trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2013;8:1084-1090.
- 30 Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase ii study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. *British journal of cancer* 2013;109:552-558.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 31 Tamiya M, Tamiya A, Yamadori T, et al. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. *Medical oncology* 2013;30:676.
- 32 Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. *Clinical breast cancer* 2013;13:416-420.
- 33 Douillard JY, Zemelka T, Fountzilias G, et al. Folfox4 with cetuximab vs. Ufox with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase ii future study. *Clinical colorectal cancer* 2014;13:14-26 e11.
- 34 von Pawel J, Harvey JH, Spigel DR, et al. Phase ii trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (trail-r1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. *Clinical lung cancer* 2014;15:188-196 e182.
- 35 Sohal DP, Mykulowycz K, Uehara T, et al. A phase ii trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:3061-3065.
- 36 Vermorken JB, Licitra L, Stohlmacher-Williams J, et al. Phase ii study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. *European journal of cancer* 2013;49:2877-2883.
- 37 Kim KB, Sosman JA, Fruehauf JP, et al. Beam: A randomized phase ii study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:34-41.
- 38 Spigel DR, Greco FA, Thompson DS, et al. Phase ii study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer. *Clinical lung cancer* 2010;11:198-203.
- 39 William WN, Jr., Kies MS, Fossella FV, et al. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. *Cancer* 2010;116:2401-2408.
- 40 Socinski MA, Scappaticci FA, Samant M, et al. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2010;5:354-360.
- 41 Infante JR, Reid TR, Cohn AL, et al. Axitinib and/or bevacizumab with modified folfox-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study. *Cancer* 2013;119:2555-2563.
- 42 Kaye SB, Poole CJ, Danska-Bidzinska A, et al. A randomized phase ii study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:145-152.
- 43 Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase ii study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the salute trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:2215-2222.
- 44 Blumenschein GR, Jr., Kabbinar F, Menon H, et al. A phase ii, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2011;22:2057-2067.
- 45 Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase iii trial bms099. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:911-917.
- 46 Peeters M, Price TJ, Cervantes A, et al. Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

colorectal cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:4706-4713.

47 Douillard JY, Siena S, Cassidy J, et al. Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The prime study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:4697-4705.

48 Valero V, Forbes J, Pegram MD, et al. Multicenter phase iii randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with her2-gene-amplified metastatic breast cancer (bcirg 007 study): Two highly active therapeutic regimens. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:149-156.

49 Aghajanian C, Blank SV, Goff BA, et al. Oceans: A randomized, double-blind, placebo-controlled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:2039-2045.

50 Cunningham D, Wong RP, D'Haens G, et al. Cediranib with mfolfox6 vs bevacizumab with mfolfox6 in previously treated metastatic colorectal cancer. *British journal of cancer* 2013;108:493-502.

51 Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (spectrum): An open-label phase 3 randomised trial. *The Lancet Oncology* 2013;14:697-710.

52 Patel JD, Socinski MA, Garon EB, et al. Pointbreak: A randomized phase iii study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage iiib or iv nonsquamous non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:4349-4357.

53 Huang J, Nair SG, Mahoney MR, et al. Comparison of folfiri with or without cetuximab in patients with resected stage iii colon cancer; ncctg (alliance) intergroup trial n0147. *Clinical colorectal cancer* 2014;13:100-109.

54 Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (geparquinto, gbg 44): A randomised phase 3 trial. *The Lancet Oncology* 2012;13:135-144.

55 Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 mrc coin trial. *Lancet* 2011;377:2103-2114.

56 Besse B, Tsao LC, Chao DT, et al. Phase ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:90-96.

57 Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase ib study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: The axtell regimen. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:785-790.

58 Kopetz S, Hoff PM, Morris JS, et al. Phase ii trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:453-459.

59 Madajewicz S, Waterhouse DM, Ritch PS, et al. Multicenter, randomized phase ii trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (ffg) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (folfox4) as first-line therapy for patients with advanced colorectal cancer. *Investigational new drugs* 2012;30:772-778.

60 Bertolini F, Malavasi N, Scarabelli L, et al. Folfox6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. *British journal of cancer* 2011;104:1079-1084.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 61 Okita NT, Esaki T, Baba E, et al. A multicenter phase ii study of the stop-and-go modified folfox6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. *Investigational new drugs* 2012;30:2026-2031.
- 62 Souglakos J, Ziras N, Kakolyris S, et al. Randomised phase-ii trial of capiri (capecitabine, irinotecan) plus bevacizumab vs folfiri (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mrcr). *British journal of cancer* 2012;106:453-459.
- 63 McCahill LE, Yothers G, Sharif S, et al. Primary mfolfox6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of nsabp trial c-10. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:3223-3228.
- 64 Nakayama G, Uehara K, Ishigure K, et al. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mfolfox6 followed by second-line folfiri in advanced colorectal cancer: A multicenter, single-arm, phase ii trial (ccog-0801). *Cancer chemotherapy and pharmacology* 2012;70:575-581.
- 65 Tsutsumi S, Ishibashi K, Uchida N, et al. Phase ii trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: The gunma clinical oncology group (gcog) trial 001 silk study. *Oncology* 2012;83:151-157.
- 66 Ducreux M, Adenis A, Pignon JP, et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (fnclcc accord 13/0503 study). *European journal of cancer* 2013;49:1236-1245.
- 67 Paz-Ares L, Balint B, de Boer RH, et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2013;8:329-337.
- 68 Nasti G, Piccirillo MC, Izzo F, et al. Neoadjuvant folfiri+bevacizumab in patients with resectable liver metastases from colorectal cancer: A phase 2 trial. *British journal of cancer* 2013;108:1566-1570.
- 69 Tezuka T, Hamada C, Ishida H, et al. Phase ii clinical study of modified folfox7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-craft study. *Investigational new drugs* 2013;31:1321-1329.
- 70 Nishina T, Takano Y, Denda T, et al. A phase ii clinical study of mfolfox6 plus bevacizumab as first-line therapy for japanese advanced/recurrent colorectal cancer patients. *Japanese journal of clinical oncology* 2013;43:1080-1086.
- 71 Gonzalez-Martin A, Gladieff L, Tholander B, et al. Efficacy and safety results from octavia, a single-arm phase ii study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. *European journal of cancer* 2013;49:3831-3838.
- 72 Deng T, Zhang L, Liu XJ, et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (folfiri) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. *Medical oncology* 2013;30:752.
- 73 Kim S, Dobi E, Jary M, et al. Bifractionated cpt-11 with lv5fu2 infusion (folfiri-3) in combination with bevacizumab: Clinical outcomes in first-line metastatic colorectal cancers according to plasma angiotensin-2 levels. *BMC cancer* 2013;13:611.
- 74 Tai CJ, Chen CS, Hung CS, et al. Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: A pilot phase ii study. *Anticancer research* 2012;32:5501-5506.
- 75 Cohn AL, Taberero J, Maurel J, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with folfiri for second-line treatment of mutant kras metastatic colorectal cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1777-1785.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 76 Berlin J, Bendell JC, Hart LL, et al. A randomized phase ii trial of vismodegib versus placebo with folfox or folfiri and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2013;19:258-267.
- 77 Allegra CJ, Yothers G, O'Connell MJ, et al. Phase iii trial assessing bevacizumab in stages ii and iii carcinoma of the colon: Results of nsabp protocol c-08. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:11-16.
- 78 Saltz L, Badarinath S, Dakhil S, et al. Phase iii trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. Folfox-bevacizumab in colorectal cancer. *Clinical colorectal cancer* 2012;11:101-111.
- 79 Pectasides D, Papaxoinis G, Kalogeras KT, et al. Xeliri-bevacizumab versus folfiri-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A hellenic cooperative oncology group phase iii trial with collateral biomarker analysis. *BMC cancer* 2012;12:271.
- 80 Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus s-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (soft): An open-label, non-inferiority, randomised phase 3 trial. *The Lancet Oncology* 2013;14:1278-1286.
- 81 Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mfolfox6 versus bevacizumab with mfolfox6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase iii study (horizon iii). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:3588-3595.
- 82 Farhat H, Reman O, Raffoux E, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia french association. *American journal of hematology* 2012;87:62-65.
- 83 Crawford J, Swanson P, Schwarzenberger P, et al. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2013;8:1510-1518.
- 84 Usui N, Takeshita A, Nakaseko C, et al. Phase i trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (aml): Japan adult leukemia study group (jalsg)-aml206 study. *Cancer science* 2011;102:1358-1365.
- 85 Reck M, Krzakowski M, Chmielowska E, et al. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (cs-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer. *Lung cancer* 2013;82:441-448.
- 86 Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. *Blood* 2013;121:4854-4860.
- 87 Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of amg 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2010;16:3044-3056.
- 88 Peeters M, Strickland AH, Lichinitser M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (amg 386) in combination with folfiri in patients with previously treated metastatic colorectal carcinoma. *British journal of cancer* 2013;108:503-511.
- 89 Chen H, Modiano MR, Neal JW, et al. A phase ii multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. *British journal of cancer* 2014;110:602-608.
- 90 Dickson MA, Shah MA, Rathkopf D, et al. A phase i clinical trial of folfiri in combination with the pan-cyclin-dependent kinase (cdk) inhibitor flavopiridol. *Cancer chemotherapy and pharmacology* 2010;66:1113-1121.
- 91 Wakelee HA, Middleton G, Dunlop D, et al. A phase i pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (nsclc). *Cancer chemotherapy and pharmacology* 2012;69:815-824.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 92 Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, et al. A phase i dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. *British journal of cancer* 2012;107:604-611.
- 93 Khayat D, Tejpar S, Spano JP, et al. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase i study. *European journal of cancer* 2013;49:790-797.
- 94 Van Cutsem E, Khayat D, Verslype C, et al. Phase i dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. *European journal of cancer* 2013;49:17-24.
- 95 Freyer G, Isambert N, You B, et al. Phase i dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. *British journal of cancer* 2012;107:598-603.
- 96 Rodon J, Jacobs CD, Chu Q, et al. A phase i pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (nsclc). *Cancer chemotherapy and pharmacology* 2012;69:825-834.
- 97 Meier W, du Bois A, Rau J, et al. Randomized phase ii trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage iib-iv. *Gynecologic oncology* 2012;126:236-240.
- 98 Dizon DS, Damstrup L, Finkler NJ, et al. Phase ii activity of belinostat (pxd-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2012;22:979-986.
- 99 Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase iii randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:3499-3506.
- 100 Tabernero J, Van Cutsem E, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the velour trial. *European journal of cancer* 2014;50:320-331.
- 101 Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase ii trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage iiib/iv non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2010;5:1963-1969.
- 102 Vergote IB, Chekkerov R, Amant F, et al. Randomized, phase ii, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:3127-3132.
- 103 Vansteenkiste J, Ramlau R, von Pawel J, et al. A phase ii randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemo-naïve patients with advanced non-small cell lung cancer. *Oncology* 2012;82:25-29.
- 104 Kelly RJ, Thomas A, Rajan A, et al. A phase i/ii study of sepantromium bromide (ym155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:2601-2606.
- 105 Fury MG, Sherman E, Ho AL, et al. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. *Cancer* 2013;119:1823-1831.
- 106 Croghan GA, Suman VJ, Maples WJ, et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: A phase 2 consortium study. *Cancer* 2010;116:3463-3468.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 107 Jabbour E, Kantarjian H, Ravandi F, et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Cancer* 2011;117:1236-1244.
- 108 Schimmer AD, Herr W, Hanel M, et al. Addition of aeg35156 xiap antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase ii study. *Clinical lymphoma, myeloma & leukemia* 2011;11:433-438.
- 109 Kollmannsberger C, Hirte H, Siu LL, et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: A ncic-ctg, phase i, open-label dose-escalation study (ind 179). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:238-244.
- 110 Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:56-62.
- 111 Laskin JJ, Nicholas G, Lee C, et al. Phase i/ii trial of custirsen (ogx-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2012;7:579-586.
- 112 Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase ii trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:2204-2210.
- 113 Chiappori AA, Schreeder MT, Moezi MM, et al. A phase i trial of pan-bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. *British journal of cancer* 2012;106:839-845.
- 114 Park S, Chapuis N, Saint Marcoux F, et al. A phase ib goelams study of the mtor inhibitor rad001 in association with chemotherapy for aml patients in first relapse. *Leukemia* 2013;27:1479-1486.
- 115 Jones SF, Infante JR, Thompson DS, et al. A phase i trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. *Cancer chemotherapy and pharmacology* 2012;70:471-475.
- 116 Hauke RJ, Infante JR, Rubin MS, et al. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: A phase ii trial of the sarah cannon research institute oncology research consortium. *Melanoma research* 2013;23:468-473.
- 117 Fruh M, Cathomas R, Siano M, et al. Carboplatin and paclitaxel plus asa404 as first-line chemotherapy for extensive-stage small-cell lung cancer: A multicenter single arm phase ii trial (sakk 15/08). *Clinical lung cancer* 2013;14:34-39.
- 118 Lara PN, Jr., Douillard JY, Nakagawa K, et al. Randomized phase iii placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (asa404) in advanced non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:2965-2971.
- 119 Aghajanian C, Sill MW, Secord AA, et al. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: A gynecologic oncology group study. *Gynecologic oncology* 2012;126:424-427.
- 120 Yamada K, Nakao M, Fukuyama C, et al. Phase i study of tlr9 agonist pf-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. *Cancer science* 2010;101:188-195.
- 121 Manegold C, van Zandwijk N, Szczesna A, et al. A phase iii randomized study of gemcitabine and cisplatin with or without pf-3512676 (tlr9 agonist) as first-line treatment of advanced non-small-cell lung cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:72-77.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 122 Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase iii trial of paclitaxel/carboplatin with or without pf-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:2667-2674.
- 123 Besse B, Heist RS, Papadimitrakopoulou VA, et al. A phase ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2014;25:505-511.
- 124 Cognetti F, Bagnato A, Colombo N, et al. A phase ii, randomized, double-blind study of zibotentan (zd4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (ago-ovar 2.14). *Gynecologic oncology* 2013;130:31-37.
- 125 Schultheis B, Kummer G, Zeth M, et al. Phase ib study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. *Cancer chemotherapy and pharmacology* 2012;69:333-339.
- 126 Brady J, Corrie P, Chau I, et al. An open-label study of the safety and tolerability of pazopanib in combination with folfox6 or capeox in patients with colorectal cancer. *Investigational new drugs* 2013;31:1228-1235.
- 127 Cabebe EC, Fisher GA, Sikic BI. A phase i trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. *Investigational new drugs* 2012;30:1082-1087.
- 128 Blumenschein GR, Jr., Reckamp K, Stephenson GJ, et al. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2010;16:279-290.
- 129 Sharma S, Abhyankar V, Burgess RE, et al. A phase i study of axitinib (ag-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21:297-304.
- 130 Kozloff MF, Martin LP, Krzakowski M, et al. Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. *British journal of cancer* 2012;107:1277-1285.
- 131 Blank SV, Christos P, Curtin JP, et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase ii study based on surgical reassessment. *Gynecologic oncology* 2010;119:451-456.
- 132 Wainberg ZA, Lin LS, DiCarlo B, et al. Phase ii trial of modified folfox6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. *British journal of cancer* 2011;105:760-765.
- 133 Aisner J, Manola JB, Dakhil SR, et al. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: A randomized phase 2 precog study (pre0501). *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2013;8:1075-1083.
- 134 Tabernero J, Garcia-Carbonero R, Cassidy J, et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified folfox6) as first-line treatment of metastatic colorectal cancer: The respect trial. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2013;19:2541-2550.
- 135 Bhatia S, Moon J, Margolin KA, et al. Phase ii trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: Swog s0512. *PloS one* 2012;7:e48787.
- 136 Xue C, Huang Y, Huang PY, et al. Phase ii study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1055-1061.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 137 Janne PA, Wang X, Socinski MA, et al. Randomized phase ii trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: Calgb 30406 trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:2063-2069.
- 138 Sun W, Powell M, O'Dwyer PJ, et al. Phase ii study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: Ecog 5203. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:2947-2951.
- 139 Pautier P, Joly F, Kerbrat P, et al. Phase ii study of gefitinib in combination with paclitaxel (p) and carboplatin (c) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839il/0074). *Gynecologic oncology* 2010;116:157-162.
- 140 Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase iii study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: Monet1. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:2829-2836.
- 141 Paz-Ares LG, Biesma B, Heigener D, et al. Phase iii, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:3084-3092.
- 142 Scagliotti G, Novello S, von Pawel J, et al. Phase iii study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:1835-1842.
- 143 Tran HT, Zinner RG, Blumenschein GR, Jr., et al. Pharmacokinetic study of the phase iii, randomized, double-blind, multicenter trial (tribute) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer (nscl). *Investigational new drugs* 2011;29:499-505.
- 144 du Bois A, Huober J, Stopfer P, et al. A phase i open-label dose-escalation study of oral bibf 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21:370-375.
- 145 Flaherty KT, Lee SJ, Zhao F, et al. Phase iii trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:373-379.
- 146 Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebo-controlled, phase iii study of first-line oxaliplatin-based chemotherapy plus ptk787/zk 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:1997-2003.
- 147 Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase iii study of oxaliplatin, fluorouracil, and leucovorin with or without ptk787/zk 222584 in patients with previously treated metastatic colorectal adenocarcinoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:2004-2010.
- 148 Advani AS, Tiu R, Saunthararajah Y, et al. A phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. *Leukemia research* 2010;34:1622-1626.
- 149 Yoshino T, Yamazaki K, Hamaguchi T, et al. Phase i study of sunitinib plus modified folfox6 in japanese patients with treatment-naive colorectal cancer. *Anticancer research* 2012;32:973-979.
- 150 Leong S, Eckhardt SG, Chan E, et al. A phase i study of sunitinib combined with modified folfox6 in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* 2012;70:65-74.
- 151 Camidge DR, Blais N, Jonker DJ, et al. Sunitinib combined with pemetrexed and cisplatin: Results of a phase i dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

cohort in non-small cell lung cancer and mesothelioma. *Cancer chemotherapy and pharmacology* 2013;71:307-319.

152 Blais N, Camidge DR, Jonker DJ, et al. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase i dose-escalation study. *Investigational new drugs* 2013;31:1487-1498.

153 Starling N, Vazquez-Mazon F, Cunningham D, et al. A phase i study of sunitinib in combination with folfiri in patients with untreated metastatic colorectal cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:119-127.

154 Reck M, Frickhofen N, Cedres S, et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase i dose-escalation study. *Lung cancer* 2010;70:180-187.

155 Tsuji Y, Satoh T, Tsuji A, et al. First-line sunitinib plus folfiri in japanese patients with unresectable/metastatic colorectal cancer: A phase ii study. *Cancer science* 2012;103:1502-1507.

156 Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase iii trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:1341-1347.

157 Lorusso P, Shields AF, Gadgeel S, et al. Cediranib in combination with various anticancer regimens: Results of a phase i multi-cohort study. *Investigational new drugs* 2011;29:1395-1405.

158 Satoh T, Yamaguchi K, Boku N, et al. Phase i results from a two-part phase i/ii study of cediranib in combination with mfolfox6 in japanese patients with metastatic colorectal cancer. *Investigational new drugs* 2012;30:1511-1518.

159 Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with folfox or folfiri as first- or second-line treatment of colorectal cancer: Results of a multicenter, phase ib study. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1560-1567.

160 Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase ii study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North central cancer treatment group study n0528. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2013;8:79-88.

161 Laurie SA, Solomon BJ, Seymour L, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: Ncic clinical trials group study br29. *European journal of cancer* 2014;50:706-712.

162 Okamoto I, Yoshioka H, Takeda K, et al. Phase i clinical study of the angiogenesis inhibitor tsu-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2012;7:427-433.

163 Heath EI, Blumenschein GR, Jr., Cohen RB, et al. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: Phase i study results. *Cancer chemotherapy and pharmacology* 2011;68:703-712.

164 Davies JM, Dhruva NS, Walko CM, et al. A phase i trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. *Lung cancer* 2011;71:151-155.

165 Vermorken JB, Rottey S, Ehrnrooth E, et al. A phase ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: Cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1392-1400.

166 Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (fastact-2): A randomised, double-blind trial. *The Lancet Oncology* 2013;14:777-786.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 167 Kato T, Muro K, Yamaguchi K, et al. Cediranib in combination with mfolfox6 in japanese patients with metastatic colorectal cancer: Results from the randomised phase ii part of a phase i/ii study. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:933-941.
- 168 Okamoto I, Miyazaki M, Morinaga R, et al. Phase i clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. *Investigational new drugs* 2010;28:844-853.
- 169 Burris HA, 3rd, Dowlati A, Moss RA, et al. Phase i study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. *Molecular cancer therapeutics* 2012;11:1820-1828.
- 170 Ravandi F, Cortes JE, Jones D, et al. Phase i/ii study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:1856-1862.
- 171 Nishio M, Horai T, Horiike A, et al. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. *British journal of cancer* 2013;109:538-544.
- 172 Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): A phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
- 173 Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase ii study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. *Lung cancer* 2012;77:567-571.
- 174 Im SA, Lee KS, Ro J, et al. Phase ii trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in her2 positive stage ii/iii breast cancer: The korean cancer study group br 07-01. *Breast cancer research and treatment* 2012;132:589-600.
- 175 Park IH, Lee KS, Kang HS, et al. A phase ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with her2 positive early breast cancer. *Investigational new drugs* 2012;30:1972-1977.
- 176 Horita Y, Yamada Y, Kato K, et al. Phase ii clinical trial of second-line folfiri plus bevacizumab for patients with metastatic colorectal cancer: Avasiri trial. *International journal of clinical oncology* 2012;17:604-609.
- 177 Yoshino T, Yamazaki K, Yamaguchi K, et al. A phase i study of intravenous aflibercept with folfiri in japanese patients with previously treated metastatic colorectal cancer. *Investigational new drugs* 2013;31:910-917.
- 178 del Carmen MG, Micha J, Small L, et al. A phase ii clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. *Gynecologic oncology* 2012;126:369-374.
- 179 Shin SJ, Jung M, Jeung HC, et al. A phase i pharmacokinetic study of tsu-68 (a multiple tyrosine kinase inhibitor of vegfr-2, fgf and pdgf) in combination with s-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. *Investigational new drugs* 2012;30:1501-1510.
- 180 Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (hercules) trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:1473-1480.
- 181 Rastogi P, Buyse ME, Swain SM, et al. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for her2- locally advanced breast cancer: A phase ii trial of the nsabp foundation research group. *Clinical breast cancer* 2011;11:228-234.
- 182 Yardley DA, Hart L, Waterhouse D, et al. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer. *Breast cancer research and treatment* 2013;142:655-665.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 183 de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (avant): A phase 3 randomised controlled trial. *The Lancet Oncology* 2012;13:1225-1233.
- 184 Bernsdorf M, Ingvar C, Jorgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase ii trial. *Breast cancer research and treatment* 2011;126:463-470.
- 185 Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase ii study. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2011;22:1358-1366.
- 186 Leone F, Artale S, Marino D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. *The metapan study. Cancer* 2013;119:3429-3435.
- 187 Lobo C, Lopes G, Baez O, et al. Final results of a phase ii study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with her2-negative metastatic breast cancer. *Breast cancer research and treatment* 2010;123:427-435.
- 188 Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (expand): A randomised, open-label phase 3 trial. *The Lancet Oncology* 2013;14:490-499.
- 189 van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage iv rectal cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:1762-1769.
- 190 Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase iii study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:3968-3976.
- 191 Doi T, Boku N, Kato K, et al. Phase i/ii study of capecitabine plus oxaliplatin (xelox) plus bevacizumab as first-line therapy in japanese patients with metastatic colorectal cancer. *Japanese journal of clinical oncology* 2010;40:913-920.
- 192 Shin SJ, Ahn JB, Park KS, et al. A phase ib pharmacokinetic study of the anti-angiogenic agent ckd-732 used in combination with capecitabine and oxaliplatin (xelox) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. *Investigational new drugs* 2012;30:672-680.
- 193 Gomez-Martin C, Salazar R, Montagut C, et al. A phase i, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. *Investigational new drugs* 2013;31:390-398.
- 194 Satoh T, Yamada Y, Muro K, et al. Phase i study of cediranib in combination with cisplatin plus fluoropyrimidine (s-1 or capecitabine) in japanese patients with previously untreated advanced gastric cancer. *Cancer chemotherapy and pharmacology* 2012;69:439-446.
- 195 Raez LE, Santos ES, Webb RT, et al. A multicenter phase ii study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (nscL). *Cancer chemotherapy and pharmacology* 2013;72:1103-1110.
- 196 Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase ii trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in her2-positive metastatic breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:976-983.
- 197 Reardon DA, Desjardins A, Peters KB, et al. Phase ii study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. *Journal of neuro-oncology* 2012;107:155-164.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 198 Spigel DR, Anthony Greco F, Waterhouse DM, et al. Phase ii trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. *Lung cancer* 2012;78:70-75.
- 199 Oh DY, Lee KW, Lee KH, et al. A phase ii trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. *Investigational new drugs* 2012;30:1164-1174.
- 200 Livingston RB, Barlow WE, Kash JJ, et al. Swog s0215: A phase ii study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for her2-positive, stage iv breast cancer. *Breast cancer research and treatment* 2011;130:123-131.
- 201 Uronis HE, Bendell JC, Altomare I, et al. A phase ii study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. *The oncologist* 2013;18:271-272.
- 202 Sanoff HK, Bernard S, Goldberg RM, et al. Phase ii study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. *Gastrointestinal cancer research : GCR* 2011;4:78-83.
- 203 Leon L, Vazquez S, Gracia JM, et al. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients. *Expert opinion on pharmacotherapy* 2012;13:1389-1396.
- 204 Merchan JR, Ferrell A, Macintyre J, et al. Phase ii study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. *American journal of clinical oncology* 2012;35:446-450.
- 205 Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. *The Lancet Oncology* 2010;11:1142-1148.
- 206 Lin C, Chen DR, Chang KJ, et al. A phase ii study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for t2 breast cancers. *Cancer chemotherapy and pharmacology* 2012;69:1363-1368.
- 207 Venturini M, Bighin C, Puglisi F, et al. A multicentre phase ii study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. *Breast* 2010;19:333-338.
- 208 Cascinu S, Berardi R, Sobrero A, et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A giscad randomized phase ii study. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 2014;46:182-186.
- 209 Hwang IG, Jang JS, Oh SY, et al. A phase ii trial of erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. *Investigational new drugs* 2012;30:2371-2376.
- 210 Starling N, Hawkes EA, Chau I, et al. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:942-947.
- 211 Chung KY, Saito K, Zergebel C, et al. Phase i study of two schedules of oral s-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. *Oncology* 2011;81:65-72.
- 212 Martin M, Sanchez-Rovira P, Munoz M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in her2-positive metastatic breast cancer patients: Efficacy and cardiac safety from the geicam/2004-05 study. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2011;22:2591-2596.
- 213 Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage iv melanoma : A north central cancer treatment group study, n0775. *Cancer* 2013;119:586-592.
- 214 Halmos B, Jia Y, Bokar JA, et al. A phase i study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. *Investigational new drugs* 2013;31:1244-1250.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 215 Garcia Alfonso P, Munoz Martin A, Alvarez Suarez S, et al. Bevacizumab in combination with capecitabine plus irinotecan as first-line therapy in metastatic colorectal cancer: A pooled analysis of 2 phase ii trials. *Onkologie* 2013;36:363-367.
- 216 Boku N, Muro K, Machida N, et al. Phase i study of sunitinib plus s-1 and cisplatin in japanese patients with advanced or metastatic gastric cancer. *Investigational new drugs* 2014;32:261-270.
- 217 El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase ii study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21:1999-2004.
- 218 LoConte NK, Holen KD, Schelman WR, et al. A phase i study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: A wisconsin oncology network study. *Investigational new drugs* 2013;31:943-948.
- 219 Lassen U, Molife LR, Sorensen M, et al. A phase i study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. *British journal of cancer* 2010;103:12-17.
- 220 Rubovszky G, Lang I, Ganofszy E, et al. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study. *European journal of cancer* 2013;49:3806-3812.
- 221 Correale P, Remondo C, Carbone SF, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. *Cancer biology & therapy* 2010;9:685-693.
- 222 Chow KU, Kim SZ, von Neuhoff N, et al. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. *European journal of haematology* 2011;87:426-433.
- 223 Fekrazad HM, Verschraegen CF, Royce M, et al. A phase i study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. *American journal of clinical oncology* 2010;33:393-397.
- 224 Kaye S, Aamdal S, Jones R, et al. Phase i study of saracatinib (azd0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. *British journal of cancer* 2012;106:1728-1734.
- 225 Koizumi W, Yamaguchi K, Hosaka H, et al. Randomised phase ii study of s-1/cisplatin plus tsu-68 vs s-1/cisplatin in patients with advanced gastric cancer. *British journal of cancer* 2013;109:2079-2086.
- 226 Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (sogug-02-06). *The Lancet Oncology* 2010;11:350-357.
- 227 Michalaki V, Fotiou S, Gennatas S, et al. Trastuzumab plus capecitabine and docetaxel as first-line therapy for her2-positive metastatic breast cancer: Phase ii results. *Anticancer research* 2010;30:3051-3054.
- 228 O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *The New England journal of medicine* 2011;364:205-214.
- 229 Tebbutt NC, Wilson K, GebSKI VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the australasian gastrointestinal trials group randomized phase iii max study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:3191-3198.
- 230 Picus J, Halabi S, Kelly WK, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: Results from cancer and leukemia group b study 90006. *Cancer* 2011;117:526-533.
- 231 Tveit KM, Guren T, Glimelius B, et al. Phase iii trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (nordic flox) versus flox alone in first-line treatment of metastatic colorectal cancer: The nordic-vii study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:1755-1762.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 232 Hahn NM, Stadler WM, Zon RT, et al. Phase ii trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group gu 04-75. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:1525-1530.
- 233 Hurwitz H, Mitchell EP, Cartwright T, et al. A randomized, phase ii trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: Xelox-a-dvs (dense versus standard). *The oncologist* 2012;17:937-946.
- 234 Kato S, Andoh H, Gamoh M, et al. Safety verification trials of mfolfiri and sequential iris + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in japanese patients. *Oncology* 2012;83:101-107.
- 235 Sehgal R, Lembersky BC, Rajasen KK, et al. A phase i/ii study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. *Clinical colorectal cancer* 2011;10:117-120.
- 236 Yamada Y, Kiyota N, Fuse N, et al. A phase i study of sorafenib in combination with s-1 plus cisplatin in patients with advanced gastric cancer. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association* 2014;17:161-172.
- 237 Falchook GS, Duvic M, Hong DS, et al. Age-stratified phase i trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. *Cancer chemotherapy and pharmacology* 2012;69:1117-1126.
- 238 Yardley D, Burris H, 3rd, Peacock N, et al. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in her2-positive patients, in the treatment of early-stage breast cancer. *Breast cancer research and treatment* 2010;123:471-475.
- 239 Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with her2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. *The Lancet Oncology* 2013;14:1121-1128.
- 240 Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose pet with clinical outcome: A phase 2 study. *The Lancet Oncology* 2010;11:48-54.
- 241 Fogelman D, Jafari M, Varadhachary GR, et al. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: A phase ii trial. *Cancer chemotherapy and pharmacology* 2011;68:1431-1438.
- 242 Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large b-cell lymphoma who are not candidates for high-dose therapy. A phase ii lymphoma study association trial. *Haematologica* 2013;98:1726-1731.
- 243 Kim C, Lee JL, Ryu MH, et al. A prospective phase ii study of cetuximab in combination with xelox (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. *Investigational new drugs* 2011;29:366-373.
- 244 Kaira K, Tomizawa Y, Yoshino R, et al. Phase ii study of oral s-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. *Lung cancer* 2013;82:103-108.
- 245 Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-sog 03 phase ii trial. *Japanese journal of clinical oncology* 2013;43:964-971.
- 246 Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First-line xelox plus bevacizumab followed by xelox plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase iii macro ttd study. *The oncologist* 2012;17:15-25.
- 247 Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + xelox treatment in previously untreated patients with metastatic colorectal cancer: Phase iii 'stop and go' study results--a turkish oncology group trial. *Oncology* 2013;85:328-335.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 248 Lee KW, Park SR, Oh DY, et al. Phase i study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. *Investigational new drugs* 2013;31:1547-1558.
- 249 Langenberg MH, Witteveen PO, Roodhart JM, et al. Phase i evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2010;16:2187-2197.
- 250 Chan A, Conte PF, Petruzelka L, et al. Phase ii study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in her2-positive metastatic breast cancer. *Anticancer research* 2013;33:2657-2664.
- 251 Kim C, Lee JL, Choi YH, et al. Phase i dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. *Investigational new drugs* 2012;30:306-315.
- 252 Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: Calgb 30306, a phase ii study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:4436-4441.
- 253 Clark JI, Greene JB, Lau Clark A, et al. Phase i pilot study of oxaliplatin, infusional 5-fu, and cetuximab in recurrent or metastatic head and neck cancer. *Medical oncology* 2013;30:358.
- 254 Woll E, Greil R, Eisterer W, et al. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase ii trial (gastric-2) of the arbeitsgemeinschaft medikamentöse tumorthherapie (agmt). *Anticancer research* 2011;31:4439-4443.
- 255 Francois E, Bennouna J, Chamorey E, et al. Phase i trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: A clinical and pharmacological study. *Chemotherapy* 2012;58:371-380.
- 256 Tsao AS, Harun N, Lee JJ, et al. Phase i trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. *Clinical lung cancer* 2014;15:197-201.
- 257 Wong NS, Fernando NH, Bendell JC, et al. A phase ii study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. *Clinical colorectal cancer* 2011;10:210-216.
- 258 Dotan E, Meropol NJ, Burtness B, et al. A phase ii study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A fox chase extramural research study. *Journal of gastrointestinal cancer* 2012;43:562-569.
- 259 Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2011;22:2042-2048.
- 260 Tan WW, Allred JB, Salim M, et al. Phase ii interventional study (n0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of her2-positive metastatic breast cancer: A north central cancer treatment group trial. *Clinical breast cancer* 2012;12:81-86.
- 261 Zigelboim I, Wright JD, Gao F, et al. Multicenter phase ii trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. *Gynecologic oncology* 2013;130:64-68.
- 262 Sun W, Sohal D, Haller DG, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. *Cancer* 2011;117:3187-3192.
- 263 Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: Aio krk-0104--a randomized trial of the german aio crc study group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:1050-1058.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 264 Guan ZZ, Xu JM, Luo RC, et al. Efficacy and safety of bevacizumab plus chemotherapy in chinese patients with metastatic colorectal cancer: A randomized phase iii artist trial. *Chinese journal of cancer* 2011;30:682-689.
- 265 Idelevich E, Kashtan H, Klein Y, et al. Prospective phase ii study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. *Onkologie* 2012;35:427-431.
- 266 Chung EK, Posadas EM, Kasza K, et al. A phase ii trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. *American journal of clinical oncology* 2011;34:150-154.
- 267 Martin LK, Bekaii-Saab T, Serna D, et al. A phase i dose escalation and pharmacodynamic study of su5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. *Onkologie* 2013;36:657-660.
- 268 Conlin AK, Seidman AD, Bach A, et al. Phase ii trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with her2-overexpressing metastatic breast cancer. *Clinical breast cancer* 2010;10:281-287.
- 269 Ellis PM, Jungnelius U, Zhang J, et al. A phase i study of pomalidomide (cc-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2013;8:423-428.
- 270 Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. *Clinical genitourinary cancer* 2013;11:175-181.
- 271 Yoo C, Ryu MH, Na YS, et al. Phase i and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. *Investigational new drugs* 2014;32:271-278.
- 272 Radford J, Davies A, Cartron G, et al. Obinutuzumab (ga101) plus chop or fc in relapsed/refractory follicular lymphoma: Results of the gaudi study (bo21000). *Blood* 2013;122:1137-1143.
- 273 Fury MG, Sherman E, Ho A, et al. A phase i study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (r/m) head and neck squamous cell cancer (hnscc). *Cancer chemotherapy and pharmacology* 2012;70:121-128.
- 274 Renouf DJ, Welch S, Moore MJ, et al. A phase ii study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Cancer chemotherapy and pharmacology* 2012;69:1339-1344.
- 275 Lepretre S, Aurran T, Mahe B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. *Blood* 2012;119:5104-5110.
- 276 Schelman WR, Mohammed TA, Traynor AM, et al. A phase i study of at-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. *Investigational new drugs* 2014;32:295-302.
- 277 Eatock MM, Tebbutt NC, Bampton CL, et al. Phase ii randomized, double-blind, placebo-controlled study of amg 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:710-718.
- 278 Lee JK, Capanu M, O'Reilly EM, et al. A phase ii study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. *British journal of cancer* 2013;109:915-919.
- 279 Mizushima T, Ide Y, Murata K, et al. A phase ii study of combined chemotherapy with 5-week cycles of s-1 and cpt-11 plus bevacizumab in patients with metastatic colon cancer. *Oncology* 2013;85:317-322.
- 280 Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. *Lancet* 2010;376:1164-1174.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 281 Reynolds C, Di Bella N, Lyons RM, et al. A phase iii trial of fludarabine, cyclophosphamide, and rituximab vs. Pentostatin, cyclophosphamide, and rituximab in b-cell chronic lymphocytic leukemia. *Investigational new drugs* 2012;30:1232-1240.
- 282 Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent b-cell nonfollicular lymphomas: Phase 2 study of the italian lymphoma foundation. *Cancer* 2012;118:3954-3961.
- 283 Komatsu Y, Yuki S, Sogabe S, et al. Phase ii study of combined chemotherapy with irinotecan and s-1 (iris) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. *Acta oncologica* 2012;51:867-872.
- 284 Karmali R, Kassar M, Venugopal P, et al. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. *Clinical lymphoma, myeloma & leukemia* 2011;11:467-474.
- 285 Saraiya B, Chugh R, Karantza V, et al. Phase i study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. *Investigational new drugs* 2012;30:258-265.
- 286 Tagawa ST, Milowsky MI, Jeske S, et al. A phase i trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New york cancer consortium trial nci 6981. *American journal of clinical oncology* 2011;34:443-448.
- 287 Morschhauser F, Mounier N, Sebban C, et al. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-hodgkin lymphoma with high tumor burden: A multicenter phase 2 trial by the groupe d'etude des lymphomes de l'adulte (gela) and groupe ouest est des leucemies et autres maladies du sang (goelams). *Cancer* 2010;116:4299-4308.
- 288 Zinzani PL, Tani M, Pulsoni A, et al. A phase ii trial of short course fludarabine, mitoxantrone, rituximab followed by (9)(0)y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2012;23:415-420.
- 289 Oshita F, Saito H, Murakami S, et al. Phase ii study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. *American journal of clinical oncology* 2010;33:66-69.
- 290 Montillo M, Tedeschi A, Petrizzi VB, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with b-cell chronic lymphocytic leukemia. *Blood* 2011;118:4079-4085.
- 291 Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:1756-1765.
- 292 Rajan A, Carter CA, Kelly RJ, et al. A phase i combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2012;18:2344-2351.
- 293 Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: Ncic clinical trials group br24 study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:49-55.
- 294 Tryfonidis K, Boukovinas I, Xenidis N, et al. A multicenter phase i-ii study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with her2-negative metastatic breast cancer. *Breast* 2013;22:1171-1177.
- 295 Perez EA, Hillman DW, Dentchev T, et al. North central cancer treatment group (ncctg) n0432: Phase ii trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21:269-274.

296 Blackhall FH, O'Brien M, Schmid P, et al. A phase i study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2010;5:1285-1288.

297 Mendivil AA, Micha JP, Brown JV, 3rd, et al. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2013;23:533-539.

298 Andre F, Campone M, O'Regan R, et al. Phase i study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:5110-5115.

299 Moroney JW, Schlumbrecht MP, Helgason T, et al. A phase i trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2011;17:6840-6846.

300 Moroney J, Fu S, Moulder S, et al. Phase i study of the antiangiogenic antibody bevacizumab and the mtor/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: Tolerance and biological activity. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2012;18:5796-5805.

301 Crown J, Kennedy MJ, Tresca P, et al. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of her2-positive metastatic breast cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:2005-2011.

302 Kotasek D, Tebbutt N, Desai J, et al. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: A phase 1b study. *BMC cancer* 2011;11:313.

303 Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic her2positive breast cancer: An nsabp foundation research program phase i study. *Cancer chemotherapy and pharmacology* 2013;72:1205-1212.

304 Schultheis B, Neumann H, Roy R, et al. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors. *International journal of clinical pharmacology and therapeutics* 2012;50:72-73.

305 Michael M, Vlahovic G, Khamly K, et al. Phase ib study of cp-868,596, a pdgfr inhibitor, combined with docetaxel with or without axitinib, a vegfr inhibitor. *British journal of cancer* 2010;103:1554-1561.

306 Hurvitz SA, Dalenc F, Campone M, et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with her2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. *Breast cancer research and treatment* 2013;141:437-446.

307 Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with her2-positive early breast cancer: A randomized phase ii cardiac safety study (tryphaena). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:2278-2284.

308 Ko AH, Youssoufian H, Gurtler J, et al. A phase ii randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. *Investigational new drugs* 2012;30:1597-1606.

309 Ning YM, Gulley JL, Arlen PM, et al. Phase ii trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:2070-2076.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 310 Schwartzberg LS, Badarinath S, Keaton MR, et al. Phase ii multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer. *Clinical breast cancer* 2014;14:161-168.
- 311 Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early her2-positive breast cancer (neosphere): A randomised multicentre, open-label, phase 2 trial. *The Lancet Oncology* 2012;13:25-32.
- 312 Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, et al. Rc0639: Phase ii study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage her2-positive breast cancer. *Breast cancer research and treatment* 2013;138:427-435.
- 313 Sher T, Ailawadhi S, Miller KC, et al. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. *British journal of haematology* 2011;154:104-110.
- 314 Wolff RA, Fuchs M, Di Bartolomeo M, et al. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. *Cancer* 2012;118:4132-4138.
- 315 Gianni L, Romieu GH, Lichinitser M, et al. Averel: A randomized phase iii trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her2-positive locally recurrent/metastatic breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:1719-1725.
- 316 Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *The New England journal of medicine* 2012;366:109-119.
- 317 Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for her2-positive operable breast cancer (nsabp protocol b-41): An open-label, randomised phase 3 trial. *The Lancet Oncology* 2013;14:1183-1192.
- 318 Somlo G, Martel CL, Lau SK, et al. A phase i/ii prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage iv her-2 positive metastatic breast cancer. *Breast cancer research and treatment* 2012;131:899-906.
- 319 Ramaswamy B, Fiskus W, Cohen B, et al. Phase i-ii study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: Evidence for vorinostat-induced tubulin acetylation and hsp90 inhibition in vivo. *Breast cancer research and treatment* 2012;132:1063-1072.
- 320 Walter RB, Medeiros BC, Gardner KM, et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: A phase i/ii study. *Haematologica* 2014;99:54-59.
- 321 Meyerhardt JA, Ancukiewicz M, Abrams TA, et al. Phase i study of cetuximab, irinotecan, and vandetanib (zd6474) as therapy for patients with previously treated metastatic colorectal cancer. *PloS one* 2012;7:e38231.
- 322 Doi T, Muro K, Yoshino T, et al. Phase 1 pharmacokinetic study of mk-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in japanese patients with advanced colorectal cancer. *Cancer chemotherapy and pharmacology* 2013;72:643-652.
- 323 Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase ii vertical study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29:3389-3395.
- 324 Azad N, Dasari A, Arcaroli J, et al. Phase i pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. *Investigational new drugs* 2013;31:345-354.
- 325 Martin M, Makhson A, Gligorov J, et al. Phase ii study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for her-2-positive locally recurrent or metastatic breast cancer. *The oncologist* 2012;17:469-475.

Supplemental Appendix for:
Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients
Mina Nikanjam et al.

- 326 Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase ii trial. *Neuro-oncology* 2010;12:508-516.
- 327 Jerusalem G, Fasolo A, Dieras V, et al. Phase i trial of oral mtor inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with her2-overexpressing metastatic breast cancer. *Breast cancer research and treatment* 2011;125:447-455.
- 328 Chinnaiyan P, Chowdhary S, Potthast L, et al. Phase i trial of vorinostat combined with bevacizumab and cpt-11 in recurrent glioblastoma. *Neuro-oncology* 2012;14:93-100.
- 329 Kordes S, Richel DJ, Klumpen HJ, et al. A phase i/ii, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. *Investigational new drugs* 2013;31:85-91.
- 330 Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-hodgkin lymphoma. *Blood* 2011;117:2807-2812.
- 331 Kelley RK, Hwang J, Magbanua MJ, et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. *British journal of cancer* 2013;109:1725-1734.
- 332 Stephens DM, Ruppert AS, Maddocks K, et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. *Leukemia research* 2013;37:1195-1199.
- 333 Hitz F, Fischer N, Pabst T, et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive b cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: Phase i results of the sakk 38/08 trial. *Annals of hematology* 2013;92:1033-1040.
- 334 Macaulay VM, Middleton MR, Protheroe AS, et al. Phase i study of humanized monoclonal antibody ave1642 directed against the type 1 insulin-like growth factor receptor (igf-1r), administered in combination with anticancer therapies to patients with advanced solid tumors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:784-791.
- 335 Lin NU, Seah DS, Gelman R, et al. A phase ii study of bevacizumab in combination with vinorelbine and trastuzumab in her2-positive metastatic breast cancer. *Breast cancer research and treatment* 2013;139:403-410.
- 336 Dang C, Lin N, Moy B, et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in her2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:2982-2988.
- 337 Mayer EL, Dhakil S, Patel T, et al. Sabre-b: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21:2370-2376.
- 338 Vlahovic G, Meadows KL, Uronis HE, et al. A phase i study of bevacizumab, everolimus and panitumumab in advanced solid tumors. *Cancer chemotherapy and pharmacology* 2012;70:95-102.
- 339 Falchook GS, Naing A, Hong DS, et al. Dual egfr inhibition in combination with anti-vegf treatment: A phase i clinical trial in non-small cell lung cancer. *Oncotarget* 2013;4:118-127.
- 340 Falchook GS, Moulder SL, Wheler JJ, et al. Dual her2 inhibition in combination with anti-vegf treatment is active in heavily pretreated her2-positive breast cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2013;24:3004-3011.
- 341 Strickler JH, Starodub AN, Jia J, et al. Phase i study of bevacizumab, everolimus, and panobinostat (lbh-589) in advanced solid tumors. *Cancer chemotherapy and pharmacology* 2012;70:251-258.